The National Guideline Clearinghouse has posted on its Web site a guideline for management of wounds in patients with lower-extremity arterial disease: http://www.guideline.gov/summary/summary.aspx?view_id=1&doc_id=12613.

Celleration, Inc, Eden Prairie, Minnesota, developer of the patented MIST Therapy System, an innovative device that uses ultrasound to heal wounds, appointed Sven A. Wehrwein, 57, to its board of directors. Wehrwein brings more than 30 years of corporate finance and operational leadership experience to the Celleration board and will serve as an outside director and chair of the audit committee.

Michael Kujak has been named Celleration's vice president of marketing. Kujak will be responsible for building Celleration's commercial marketing organization to expand MIST Therapy's footprint and use in the US acute health care market while accelerating Celleration's ultrasound technology into broader clinical applications. Kujak brings more than 20 years of marketing and sales experience in the medical device, pharmaceutical, and biotechnology industries.

[black up pointing small triangle]Information:http://www.celleration.com